Treatment of <i>Pseudomonas</i> by Removal of Cloaking Antibodies: Is Common Polysaccharide Antigen a Factor?
This investigation reveals that although antibody specific for CPA is prevalent in pwCF, it cannot inhibit complement-killing of the majority of CPA expressing strains. Thus, when treating Pseudomonas by removing cloaking antibodies, it is unlikely that CPA-specific antibodies will also need to be eliminated.
Authors
- Simon Hall Apte (ORCID: https://orcid.org/0000-0003-3105-0820)
- Ian R. Henderson (ORCID: https://orcid.org/0000-0002-9954-4977)
- Daniel C. Chambers (ORCID: https://orcid.org/0000-0002-9553-5870)
- Michelle N. Chamoun (ORCID: https://orcid.org/0009-0006-4595-8871)
- Joanna B. Goldberg (ORCID: https://orcid.org/0000-0002-5285-5188)
- Emma L. Ledger (ORCID: https://orcid.org/0000-0002-3488-5252)
- Joshua N. Monteith (ORCID: https://orcid.org/0000-0002-1356-3852)
- Daniel Smith
- Timothy J Wells
Institutions
- The University of Queensland (AU)
- Cystic Fibrosis Foundation (US)
- Cystic Fibrosis Trust (GB)
- Prince Charles Hospital (AU)
- Prince Charles Hospital (GB)
- Indiana University School of Medicine
Publication Details
- Journal
- The Journal of Infectious Diseases
- Published
- 2026-01-05
- DOI
- https://doi.org/10.1093/infdis/jiag002
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Australian Government